Skip to content
AMR Drug RepurposingSmart Screeningresearch prototype

Carvedilol

FDA-approved product (tablet, oral), marketed as Carvedilol, Coreg, Carvedilol Phosphate and 1 more.

Registered studies
50+
Lab records
0
Pathogens at ≥40%
1 of 4

Chemical structure

Chemical structure of Carvedilol
A drawing shows what the molecule is, not what it does.

Existing / approved use

Documented · FDA, WHO, ChEMBL

Approved for

  • Cardiovascular disease
  • Congestive heart failure
  • Heart failure
  • Hypertension
  • Myocardial infarction
  • Ventricular Dysfunction, Left

Indications ChEMBL records as approved, from FDA and DailyMed labels. Label ↗

WHO therapeutic group
Alpha and beta blocking agents
FDA pharmacologic class
alpha-Adrenergic Blocker; beta-Adrenergic Blocker FDA label ↗
Anti-infective classification
Not classified as an anti-infective.

Repurposing investigation

This medicine is being investigated here for AI-predicted antimicrobial activity against M. tuberculosis. It was surfaced computationally for further investigation; it is not an established treatment for this infection.

AI-predicted activity

AI prediction · nothing measured
  • MRSA25.9% AI-predicted activityBelow the ≥40% mark this site uses to surface candidates.
  • E. coli28.4% AI-predicted activityBelow the ≥40% mark this site uses to surface candidates.
  • K. pneumoniae16.6% AI-predicted activityBelow the ≥40% mark this site uses to surface candidates.
  • M. tuberculosis55.4% AI-predicted activityAt or above the ≥40% mark this site uses to surface candidates.

A model’s estimate of laboratory activity against each pathogen species. It is not clinical effectiveness.

Evidence

Clinical and experimental

Documented evidence

Clinical

50+registered studies name this medicine, for any condition. The registry search keeps the first 50, so there may be more. See them below.

Experimental

No evidence found

No laboratory measurement against the four pathogens in the ChEMBL records loaded here.

Open Carvedilol in ChEMBL Registered studies below

Docking

Computational · nothing measured

Dihydrofolate reductase ↗ (E. coli)

Not yet docked: queued in the docking rundetails

KPC-2 carbapenemase ↗ (K. pneumoniae)

Not yet docked: queued in the docking rundetails

Enoyl-ACP reductase (InhA) ↗ (M. tuberculosis)

Not yet docked: queued in the docking rundetails

Dihydrofolate reductase ↗ (MRSA)

Not yet docked: queued in the docking rundetails

AutoDock Vina, one experimentally solved protein per pathogen. This project’s screening target is -7.0 kcal/mol, its own mark rather than a universal cutoff. A docking score is a structural hypothesis, not proof of binding, and requires experimental validation.

Other medicines to investigate

AI prediction · nothing measured

Other repurposing candidates: approved medicines besides Carvedilol with AI-predicted activity ≥40% against the chosen pathogen, leaving out existing antimicrobials. They are computational candidates for further investigation, not alternatives and not recommendations.

Sorted by AI-predicted activity, high to low. The order is not a ranking of which medicine is better.

Registered studies

A registration describes a study; it does not establish a positive result.

  • Impact of Bariatric Surgery on Pharmacokinetic Study of Simvastatin and Carvedilol

    NCT04049786 · start 2019-06-01

    Registered record
    Registry ID
    NCT04049786
    Conditions
    Obesity; Bariatric Surgery; Roux-en Y Gastric Bypass
    Interventions
    Digestive biopsy; Carvedilol 25mg; Serial blood sampling for PK analysis; Metoprolol 100 mg for CYP2D6 phenotyping; Simvastatin 40mg; Midazolam 2 mg for CYP3A4 phenotyping; Genotyping
    Study type
    INTERVENTIONAL
    Phase
    Phase 4
    Registry status
    Unknown
    Start
    2019-06-01
    Completion
    2023-08
    Enrolment
    120

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionObesity; Bariatric Surgery; Roux-en Y Gastric Bypass
    InterventionDigestive biopsy; Carvedilol 25mg; Serial blood sampling for PK analysis; Metoprolol 100 mg for CYP2D6 phenotyping +3 more
    PhasePhase 4
    Registry statusUnknown

  • Effects of Sleep Deprivation and Adrenergic Inhibition on Glymphatic Flow in Humans

    NCT03576664 · start 2018-08-28

    Registered record
    Registry ID
    NCT03576664
    Conditions
    Sleep Deprivation; Sleep Wake Disorders; Sleep
    Interventions
    Carvedilol 25mg; Placebo oral capsule
    Study type
    INTERVENTIONAL
    Phase
    Early phase 1
    Registry status
    Completed
    Start
    2018-08-28
    Completion
    2019-10-01
    Enrolment
    22

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionSleep Deprivation; Sleep Wake Disorders; Sleep
    InterventionCarvedilol 25mg; Placebo oral capsule
    PhaseEarly phase 1
    Registry statusCompleted

  • Detecting and Treating Subclinical Anthracycline Therapy Related Cardiac Dysfunction in Low Income Country.

    NCT03542058 · start 2018-06

    Registered record
    Registry ID
    NCT03542058
    Conditions
    Chemotherapy Related Cardiac Dysfunction
    Interventions
    Carvedilol
    Study type
    INTERVENTIONAL
    Phase
    Phase 3
    Registry status
    Unknown
    Start
    2018-06
    Completion
    2021-06
    Enrolment
    50

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionChemotherapy Related Cardiac Dysfunction
    InterventionCarvedilol
    PhasePhase 3
    Registry statusUnknown

  • Carvedilol for Prevention of Esophageal Varices Progression

    NCT03736265 · start 2017-10-09

    Registered record
    Registry ID
    NCT03736265
    Conditions
    Cirrhosis, Liver; Portal Hypertension
    Interventions
    Carvedilol
    Study type
    INTERVENTIONAL
    Phase
    Not applicable
    Registry status
    Unknown
    Start
    2017-10-09
    Completion
    2022-12-30
    Enrolment
    240

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionCirrhosis, Liver; Portal Hypertension
    InterventionCarvedilol
    PhaseNot applicable
    Registry statusUnknown

  • Rate Control in Atrial Fibrillation

    NCT02251509 · start 2016-12

    Registered record
    Registry ID
    NCT02251509
    Conditions
    Atrial Fibrillation
    Interventions
    Carvedilol; Metoprolol tartrate
    Study type
    INTERVENTIONAL
    Phase
    Phase 4
    Registry status
    Unknown
    Start
    2016-12
    Completion
    2017-09
    Enrolment
    20

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionAtrial Fibrillation
    InterventionCarvedilol; Metoprolol tartrate
    PhasePhase 4
    Registry statusUnknown

  • Left Cardiac Sympathetic Denervation for Cardiomyopathy Feasibility Pilot Study

    NCT03071653 · start 2016-11-24

    Registered record
    Registry ID
    NCT03071653
    Conditions
    Dilated Cardiomyopathy; Ischemic Cardiomyopathy; Non-ischemic Cardiomyopathy
    Interventions
    Left Cardiac Sympathetic Denervation (LCSD); Optimal Medical Therapy
    Study type
    INTERVENTIONAL
    Phase
    Phase 2
    Registry status
    Suspended
    Start
    2016-11-24
    Completion
    2022-02
    Enrolment
    30

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionDilated Cardiomyopathy; Ischemic Cardiomyopathy; Non-ischemic Cardiomyopathy
    InterventionLeft Cardiac Sympathetic Denervation (LCSD); Optimal Medical Therapy
    PhasePhase 2
    Registry statusSuspended

  • Beta-blockers in Pulmonary Arterial Hypertension

    NCT02507011 · start 2016-01-31

    Registered record
    Registry ID
    NCT02507011
    Conditions
    Pulmonary Arterial Hypertension
    Interventions
    Carvedilol; Placebo
    Study type
    INTERVENTIONAL
    Phase
    Phase 2
    Registry status
    Terminated
    Start
    2016-01-31
    Completion
    2019-07-01
    Enrolment
    2

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionPulmonary Arterial Hypertension
    InterventionCarvedilol; Placebo
    PhasePhase 2
    Registry statusTerminated

  • The Effect of Carvedilol VS Endoscopic Therapy in Primary Prophylaxis of High-risk Esophageal Gastric Variceal Bleeding

    NCT02695732 · start 2015-12

    Registered record
    Registry ID
    NCT02695732
    Conditions
    Liver Cirrhosis; Esophageal and Gastric Varices
    Interventions
    Carvedilol; endoscopy
    Study type
    INTERVENTIONAL
    Phase
    Phase 4
    Registry status
    Unknown
    Start
    2015-12
    Completion
    2018-09
    Enrolment
    792

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionLiver Cirrhosis; Esophageal and Gastric Varices
    InterventionCarvedilol; endoscopy
    PhasePhase 4
    Registry statusUnknown

  • Removal of Beta Blocker Drugs by Hemodialysis

    NCT03361280 · start 2015-02-27

    Registered record
    Registry ID
    NCT03361280
    Conditions
    Chronic Kidney Diseases
    Interventions
    Beta blocker
    Study type
    INTERVENTIONAL
    Phase
    Phase 1 / Phase 2
    Registry status
    Completed
    Start
    2015-02-27
    Completion
    2016-03-10
    Enrolment
    8

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionChronic Kidney Diseases
    InterventionBeta blocker
    PhasePhase 1 / Phase 2
    Registry statusCompleted

  • Mechanisms of Refractory Hypertension (Carvedilol)

    NCT02357004 · start 2015-02

    Registered record
    Registry ID
    NCT02357004
    Conditions
    Hypertensive
    Interventions
    Carvedilol; Chlorthalidone
    Study type
    INTERVENTIONAL
    Phase
    Not applicable
    Registry status
    Withdrawn
    Start
    2015-02
    Completion
    2020-01-31
    Enrolment
    0

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionHypertensive
    InterventionCarvedilol; Chlorthalidone
    PhaseNot applicable
    Registry statusWithdrawn

  • Early Precise Diagnosis and Intervention of CPT Based on a Noninvasive 3D-vHPS

    NCT02925975 · start 2015-01

    Registered record
    Registry ID
    NCT02925975
    Conditions
    Portal Hypertension; Cirrhosis
    Interventions
    Carvedilol; 3D-vHPS; Routine endoscopic procedures
    Study type
    INTERVENTIONAL
    Phase
    Phase 4
    Registry status
    Unknown
    Start
    2015-01
    Completion
    2020-06
    Enrolment
    100

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionPortal Hypertension; Cirrhosis
    InterventionCarvedilol; 3D-vHPS; Routine endoscopic procedures
    PhasePhase 4
    Registry statusUnknown

  • Doppler Ultrasound Hepatic Vein Waveform as a Non-invasive Tool in the Assessment of Severity of Portal Hypertension

    NCT02975323 · start 2014-12

    Registered record
    Registry ID
    NCT02975323
    Conditions
    Portal Hypertension
    Interventions
    Carvedilol
    Study type
    INTERVENTIONAL
    Phase
    Phase 3
    Registry status
    Unknown
    Start
    2014-12
    Completion
    2018-12
    Enrolment
    50

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionPortal Hypertension
    InterventionCarvedilol
    PhasePhase 3
    Registry statusUnknown

  • Systematic Withdrawal of Neurohumoral Blocker Therapy in Optimally Responding CRT Patients

    NCT02200822 · start 2014-07

    Registered record
    Registry ID
    NCT02200822
    Conditions
    Heart Failure (HF)
    Interventions
    beta blockers; RAAS blockers
    Study type
    INTERVENTIONAL
    Phase
    Phase 4
    Registry status
    Completed
    Start
    2014-07
    Completion
    2019-02
    Enrolment
    80

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionHeart Failure (HF)
    Interventionbeta blockers; RAAS blockers
    PhasePhase 4
    Registry statusCompleted

  • A Study in Healthy Volunteers to Evaluate the Application of Stable Isotope Approach to Reduce Number of Subjects Needed for PK Studies

    NCT01793870 · start 2013-01-15

    Registered record
    Registry ID
    NCT01793870
    Conditions
    Metabolic, Cardiovascular
    Interventions
    Tab carvedilol 25 mg; Tab carvedilol 6.25 mg; Powder carvedilol up to 2.5 mg
    Study type
    INTERVENTIONAL
    Phase
    Phase 1
    Registry status
    Completed
    Start
    2013-01-15
    Completion
    2013-06-17
    Enrolment
    17

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionMetabolic, Cardiovascular
    InterventionTab carvedilol 25 mg; Tab carvedilol 6.25 mg; Powder carvedilol up to 2.5 mg
    PhasePhase 1
    Registry statusCompleted

  • Remission From Stage D Heart Failure

    NCT01774656 · start 2013-01

    Registered record
    Registry ID
    NCT01774656
    Conditions
    Heart Failure NYHA Class III; Heart Failure NYHA Class IV
    Interventions
    Pharmacological Treatment
    Study type
    INTERVENTIONAL
    Phase
    Phase 4
    Registry status
    Unknown
    Start
    2013-01
    Completion
    2017-12
    Enrolment
    40

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionHeart Failure NYHA Class III; Heart Failure NYHA Class IV
    InterventionPharmacological Treatment
    PhasePhase 4
    Registry statusUnknown